Dyne Therapeutics
http://www.dyne-tx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Dyne Therapeutics
Finance Watch: J.P. Morgan Conference To Offer Glimpse Of 2024 Funding Forecast
Public Company Edition: Discussions at the J.P. Morgan Healthcare Conference 8-11 January in San Francisco should offer some insight on industry’s and investors’ expectations about the financial markets in 2024. The year started with some big financings, but also some new job cuts.
AMO Pharma Shows Weakness In Myotonic Dystrophy
A pivotal miss leaves the company more reliant on earlier-stage pipeline programs as it talks to regulators about the path forward for its lead product.
Avidity’s Phase I/II Success In Myotonic Dystrophy Obscured By Caveats
The US firm’s lead antibody oligonucleotide conjugate candidate has improved muscle strength and mobility in an early muscular dystrophy trial but some experts are disappointed by dose-specific data and a serious adverse event.
ADCs Coming Of Age: Deals, Targets And Catalysts
The antibody-drug conjugate field is beginning to reach its full potential and big pharma’s attention has been caught.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
-
Large Molecule
- Antibodies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice